Denali Therapeutics Inc. (NasdaqGS:DNLI) announced that it has entered into common stock purchase agreement with new investor Takeda Pharmaceutical Company Limited (TSE:4502) for the private placement of 4,214,559 shares at a price of $26.10 for the gross proceeds of $110,000,000 on January 3, 2018. The transaction is expected to close within ten business day. The securities issued are restricted for transfer including a restriction on acquiring more than 10% for a specified period of time following the closing of the sale of the shares.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
23.01 USD | -3.88% |
|
+6.28% | +7.22% |
01/07 | Denali Therapeutics Inc.(NasdaqGS:DNLI) added to Russell Small Cap Comp Value Index | CI |
01/07 | Denali Therapeutics Inc.(NasdaqGS:DNLI) added to Russell 3000 Value Index | CI |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+7.22% | 3.41B | |
+20.03% | 126B | |
+23.61% | 118B | |
+23.26% | 27.87B | |
-18.07% | 20.95B | |
-15.13% | 16.92B | |
-14.81% | 16.18B | |
+9.78% | 14.84B | |
-46.10% | 14.79B | |
+52.34% | 14.08B |
- Stock Market
- Equities
- DNLI Stock
- News Denali Therapeutics Inc.
- Denali Therapeutics Inc. announced that it expects to receive $110 million in funding from Takeda Pharmaceutical Company Limited